As of today (2024-04-25), Incyte's share price is $51.74. Incyte's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $21.90. Hence, Incyte's Price to Tangible Book Ratio of today is 2.36.
The historical rank and industry rank for Incyte's Price-to-Tangible-Book or its related term are showing as below:
INCY'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.34 Med: 8.38 Max: 118.27
Current: 2.36
During the past 13 years, Incyte's highest Price to Tangible Book Ratio was 118.27. The lowest was 2.34. And the median was 8.38.
INCY's Price-to-Tangible-Book is ranked better than 54.84% of 1220
companies
in the Biotechnology industry
Industry Median: 2.67
vs INCY: 2.36
A closely related ratio is called PB Ratio. As of today, Incyte's share price is $51.74. Incyte's Book Value per Sharefor the quarter that ended in Dec. 2023 was $23.14. Hence, Incyte's P/B Ratio of today is 2.24.
Incyte Price-to-Tangible-Book Historical Data
The historical data trend for Incyte's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Incyte's Price-to-Tangible-Book
For the Biotechnology subindustry, Incyte's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incyte's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Incyte's Price-to-Tangible-Book falls into.
Incyte Price-to-Tangible-Book Calculation
Incyte's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Incyte Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Incyte's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INCY has been successfully added to your 